# Sorafenib and TRC105 in Hepatocellular Cancer

> **NCT01306058** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 27 (actual)

## Conditions studied

- Hepatoma
- Liver Neoplasms
- Adenoma, Liver Cell
- Carcinoma, Hepatocellular
- Liver Neoplasms, Experimental

## Interventions

- **DRUG:** TRC 105
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT01306058
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02-11
- **Primary completion:** 2016-06-01
- **Final completion:** 2017-06-09
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2019-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01306058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01306058, "Sorafenib and TRC105 in Hepatocellular Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01306058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*